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OBJECTIVES We sought to evaluate whether increased sympathetic outflow may interfere with flow-
mediated dilation (FMD).
BACKGROUND Endothelial function, assessed as FMD, is frequently used as an intermediate end point in
intervention studies. Many disease states with increased sympathetic tone are also character-
ized by endothelial dysfunction.
METHODS Sixteen healthy volunteers underwent FMD studies with and without concomitant sympa-
thetic stimulation. Intra-arterial nitroglycerin (NTG) infusion was used to assess
endothelium-independent vasodilation. Pathophysiologically relevant sympathetic stimula-
tion was achieved by baroreceptor unloading, using a lower body negative pressure box. In a
subset of eight volunteers, this protocol was repeated during loco-regional alpha-adrenergic
blockade by intra-arterial infusion of phentolamine (PE). Reactive hyperemic flow was
assessed with strain-gauge phlethysmography.
RESULTS Overall, FMD responses (8.3  3.4%) were significantly attenuated by concomitant
sympathetic stimulation (3.6  3.4%, p  0.01). Loco-regional alpha-adrenergic blockade
had no effect on baseline FMD responses (10.7  4.7%), whereas the attenuation by
sympathetic stimulation was abolished completely during PE co-infusion (11.5  3.3%).
During intra-arterial NTG infusions, arterial diameters relative to baseline were not
significantly different between the four possible stages.
CONCLUSIONS Sympathetic stimulation, at a clinically relevant range, significantly impairs the FMD
response by an alpha-adrenergic mechanism. (J Am Coll Cardiol 2002;39:683–8) © 2002
by the American College of Cardiology
It has been generally accepted that endothelial dysfunction
represents a hallmark in the development of atherosclerosis.
All major risk factors that have been identified in epidemi-
ologic studies have been shown to be associated with
impaired endothelial function. Reduced endothelial re-
sponses can be observed early in the course of atherogenesis
(1), before structural lesions can be found (2). More re-
cently, endothelial dysfunction has been shown to have a
clear predictive value for future cardiovascular disease (3,4).
Although several invasive tests have been employed success-
fully for the assessment of endothelial function over the last
two decades, attention has now focused predominantly on
noninvasive techniques. Thus, assessment of flow-mediated
dilation (FMD) of the brachial artery, using an ultrasound
device, has received much attention as a tool to evaluate
endothelial function noninvasively. Using this technique,
numerous studies have shown that impaired FMD re-
sponses are associated with a wide range of cardiovascular
risk factors (1,4–6), although the impairment is reversible
with specific drug interventions (7,8).
Over the past few decades, the importance of the sym-
pathetic nervous system as a determinant of vascular tone
and as an indicator of adverse cardiovascular outcomes has
been generally accepted (7–9). Interestingly, many of the
risk factors associated with impaired FMD responses are
also characterized by increased sympathetic activity (10,11).
In addition, many of the drug interventions associated with
improvement of FMD responses may also result in sympa-
thicolysis. For example, heart failure is clearly associated
with impaired FMD responses, as well as activation of
sympathetic activity (12). Consequently, all effective thera-
peutic interventions for this condition will invariably result
in sympathicolysis. Moreover, we recently demonstrated
that specific agents, such as angiotensin-converting enzyme
inhibitors, also have direct symphathicolytic effects (13,14).
Endothelial function, as measured with FMD, has been
shown to have a diurnal effect (i.e., FMD is low when
sympathetic activation is considered to be high) (15–17).
Therefore, if sympathetic activation results in a reduced
FMD response, this may have direct consequences for the
interpretation of an impaired FMD response as an indicator
of endothelial dysfunction.
To evaluate whether and to what extent increased sym-
pathetic activity interferes with FMD, we studied FMD in
healthy volunteers at baseline and during sympathetic acti-
vation induced by baroreceptor unloading. In a subset of
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subjects, the experiments were repeated during local intra-
arterial alpha-adrenergic blockade by phentolamine (PE)
infusion.
METHODS
This study was designed to evaluate the interaction between
endothelium-dependent vasodilation and the sympathetic
system at the level of the conduit arteries.
For stimulation of the sympathetic nervous system, lower
body negative pressure (LBNP) was selected, as it is a widely
accepted, well-validated model for sympathetic activation
that allows careful standardization (18). All measurements
were performed in a quiet, temperature-controlled room.
The study was approved by the Institutional Review Com-
mittee of the University Medical Center of Utrecht. All
subjects gave written, informed consent. The procedures
followed were in accordance with institutional guidelines.
Study group. The studies were performed in 16 healthy,
nonsmoking volunteers (Table 1). None of the volunteers
used medication. All of the volunteers were free of signs
indicative of atherosclerosis on physical examination and
had a normal electrocardiogram. Blood testing excluded any
individual with: 1) cholesterol over 6.0 mmol/l; 2) triglyc-
erides over 2.0 mmol/l; 3) glycosylated hemoglobin over
6.0%; and 4) renal function outside of the laboratory’s
standard values. Urine samples from all volunteers were
tested for drug abuse. Caffeine-containing beverages were
not allowed within 12 h before the measurements took
place.
Protocol outline. In the first eight volunteers, the effect of
LBNP on FMD and forearm blood flow (FBF) was assessed
in a two-day experiment with a one-week interval. Volun-
teers were asked to lie down in the LBNP box (see
subsequent paragraph), and the protocol was re-explained to
them. Next, at baseline, the FMD of their right brachial
artery (dominant arm) was measured (see subsequent para-
graph). After a 1-h rest period, negative pressure was
introduced gradually until the heart rate had increased 15%
relative to baseline values, or until LBNP reached 20 mm
Hg. After obtaining a stable heart rate increase for 10 min,
the second FMD measurement was performed, after which
the study day ended. After one week, a similar experiment
was repeated by applying the same LBNP steps, substituting
FMD for FBF measurements to obtain reactive hyperemia
flow rates using strain-gauge plethysmography (see subse-
quent paragraph).
In the second eight volunteers, the effect of LBNP on
FMD was repeated with and without loco-regional alpha-
adrenergic blockade in a single-day experiment. The volun-
teers were placed in the LBNP box, and a cannula was
inserted in their dominant (i.e., right brachial) artery. A
period of 45 min was allowed to regain a stable baseline
condition. All volunteers underwent, in random order,
FMD measurement alone and FMD measurement with
LBNP, or FMD with PE and FMD with PE plus LBNP.
At the end of each period, nitroglycerin (NTG) was infused
at 20 g/min for 5 min, after which the brachial diameter
was measured. Phentolamine was administered locally in the
brachial artery at a rate of 100 g in 5 min, followed by a
maintenance infusion of 25 g in 5 min (19). In between
the measurement blocks, a period of 60 min of rest was
allowed to re-establish baseline conditions. During this
period, volunteers remained supine.
FMD. Flow-mediated dilation was assessed using a Wall-
tracking system (WTS2, PIE Medical, Maastricht, The
Netherlands), as published previously (8,20,21). In short,
the brachial artery diameter at the level of the antecubital
crease was measured before and 4 min after forearm occlu-
sion. To minimize mental stress, care was taken to make the
volunteers as comfortable as possible. The object arm was
stabilized with cushions, and the ultrasound probe was
fixated in the three-dimensional space using a custom-built
probe holder. The brachial artery was scanned in a longi-
tudinal window, according to previously described criteria
(20). Before occluding the forearm with a standard blood
pressure cuff, at least four serial measurements were taken.
Next, the blood pressure cuff was inflated for 4 min at 200
mm Hg and released abruptly. Post-occlusion diameters
were obtained at 45, 75, 105, 135 and 165 s after deflation.
Flow-mediated dilation was calculated as the maximal
post-occlusion diameter relative to the averaged pre-
occlusion diameters. Of note, the reproducibility of the
brachial artery diameter during the session has a coefficient
of variation of 1.1% (20).
Abbreviations and Acronyms
ANOVA  analysis of variance
FBF  forearm blood flow
FMD  flow-mediated dilation
LBNP  lower body negative pressure
MSNA  muscle sympathetic nerve activity
NO  nitric oxide
NTG  nitroglycerin
PE  phentolamine
Table 1. Volunteer Characteristics
Age (yrs) 27.5  5.1
Blood pressure (mm Hg)
Systolic 112  4.7
Diastolic 69  2.8
Creatinine (mol/l) 72.6  9.3
Urea (mmol/l) 5.0  1.7
Total cholesterol (mmol/l) 5.0  0.7
HDL cholesterol (mmol/l) 1.7  0.5
Triglycerides (mmol/l) 1.2  0.6
HbAlc (%) 5.3  0.43
BMI (kg/m2) 26.5  3.2
Gender (male/female) 12/4
Data are presented as the mean value  SD, except for gender (n).
BMI  body mass index; HbA1c  glycosylated hemoglobin; HDL  high-
density lipoprotein.
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Sympathetic activation. Sympathetic activation was elic-
ited using a LBNP box, as described previously by us and
other groups (14,18,22,23). In short, volunteers were supine
in this airtight box from the level of the iliac crest. Suction
was applied gradually with increments of 5 mm Hg, until
the heart rate increased by at least 15% or a level of
20 mm Hg of LBNP was reached. At each level, there
was a pause of at least 10 min before applying the next
level. The FMD and FBF studies were performed at least
5 min after stabilization of heart rate and blood pressure
during LBNP.
FBF measurements. Forearm blood flow was measured
with venous occlusion phlethysmography using a fully
automated R-wave–triggered system, as published previ-
ously (24). Mercury in Silastic strain gauges was placed at
the widest part of the forearm. Flow was registered at 10-s
intervals. The occlusion cuff for reactive hyperemia was
placed at the same level as used for FMD measurements,
just distal to the strain gauges. The upper arm-collecting
cuffs were inflated intermittently to 40 mm Hg by the
system.
Statistical analysis. Flow-mediated dilation was calculated
as the difference between the maximal post-occlusive diam-
eter and the average baseline diameter, relative to the
average baseline diameter, and expressed as a percentage.
All results are expressed as the mean value  SD.
Differences in baseline FMD, blood pressure, heart rate
and brachial artery diameter at baseline were tested with the
paired t test. The effect of LBNP on FMD (Fig. 1) and
heart rate (Fig. 2) was tested using one-way repeated
measures analysis of variance (ANOVA). Differences in
reactive hyperemic blood flow during rest and LBNP (Fig.
2A), as well as differences in the FMD/NTG response
without and with PE (Fig. 3), were evaluated using two-way
repeated measures ANOVA (using SAS proc mixed assum-
ing unstructured covariance matrices) (SAS Institute, Cary,
North Carolina). If the F test reached statistical signifi-
cance, differences between the mean values were analyzed
with a one degree-of-freedom test for p  0.05.
RESULTS
Effect of LBNP on FMD. Both the first and second
cohorts of eight volunteers underwent FMD testing with
and without LBNP at 20 mm Hg. In these 16 volunteers,
FMD without LBNP was 8.3  3.4%, and with concom-
itant LBNP, 3.6  3.4% (p  0.0008) (Fig. 1). During
LBNP, the mean heart rate increased from 64.4  10.8
beats/min to 75.8 12.6 beats/min (p 0.0013) (Fig. 2B).
In the subgroup that underwent FBF measurements, base-
line blood flow during LBNP was reduced from 3.2  1.0
to 2.0  0.6 ml/100 ml forearm tissue per min (Fig. 2A).
Using two-way repeated measures ANOVA, we have
shown that the statistically significant increase in FBF
Figure 1. Effect of lower body negative pressure (LBNP) on flow-mediated
dilation. Flow-mediated dilation decreased significantly during LBNP
(20 mm Hg) in healthy volunteers (*p  0.0008 by the paired t test).
Bold line  average value of all observations.
Figure 2. Effect of lower body negative pressure (LBNP) on reactive
hyperemic flow and heart rate. (A, left) Basal and maximal post-ischemic
flow at baseline. (A, right) Basal flow and maximal post-ischemic flow
during LBNP. The increase in blood flow during hyperemia was not
significantly different between baseline and LBNP (p  0.099 by two-way
repeated measures analysis of variance). (B) Lower body negative pressure
significantly increased the heart rate (*p  0.0013 by the paired t test).
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during reactive hyperemia (i.e., the stimulus for the FMD
response) was not significantly different during LBNP, as
compared with that in the control experiments (p  0.099)
(Fig. 2A). Blood pressures remained stable throughout the
experiments (mean arterial pressure [MAP] 106.6  2.8
mm Hg at baseline vs. 108.3  5.2 mm Hg during LBNP;
p  NS).
Effect of PE on LBNP effects. The baseline FMD re-
sponse did not change significantly during PE infusion
(9.8  2.7% vs. 10.7  4.7%; p  NS by the paired t test).
In contrast, the decrease in FMD during LBNP could no
longer be demonstrated during PE co-infusion (control vs.
PE: p  0.046 by two-way repeated measures ANOVA)
(Fig. 3A). Endothelium-independent vasodilation with
NTG infusion was 22.7  5.3% at baseline. Lower body
negative pressure did not significantly change the NTG
vasodilator response. Phentolamine infusion had no signif-
icant effect on the NTG response (Fig. 3B).
Local infusion of intra-arterial PE and NTG had no
effect on heart rate and/or systemic MAP. Baseline arterial
diameters did not change significantly (2.834  0.351 mm
at baseline, 2.846  0.374 mm with LBNP, 2.951  0.335
mm with PE and 2.984  0.317 mm with both LBNP and
PE).
DISCUSSION
The present study shows that sympathetic stimulation
evoked by baroreceptor unloading markedly reduces flow-
mediated vasodilation, whereas the response to exogenous
nitric oxide (NO) remains unaffected during LBNP. Local
alpha-adrenergic receptor blockade prevents the LBNP-
induced reduction in FMD.
LBNP as a stimulus for sympathetic activation. Lower
body negative pressure has been extensively validated as a
model to elicit sympathetic stimulation. Thus, muscle sym-
pathetic nerve activity (MSNA) recorded in either the
peroneal nerve or radial nerve has been shown to increase
similarly at 20 mm Hg of LBNP (25). At a level of 20
mm Hg, we and others (26) have shown a significant rise in
MSNA, without significant changes in cardiac output or
blood pressure (25–28). Noradrenalin spillover studies (23)
have also shown a significant increase in noradrenalin
production already at a level of 15 mm Hg of LBNP.
Healthy volunteers exposed to 20 mm Hg of LBNP have
been shown to have a mean heart rate increase of 15%, as
well as an increase in MSNA (19  8 bursts/100 heartbeats
at rest vs. 58  13 bursts/100 heart beats during 20 mm
Hg of LBNP [22]). These MSNA values during LBNP are
comparable to those in patient groups characterized by
increased endogenous sympathetic outflow (e.g., patients
with renal failure) (53  8 bursts/100 heart beats) (14).
Based on these data, we can safely assume that we have
elicited sympathetic activation at clinically relevant levels,
using a well-validated method.
Interaction of sympathetic nervous system with endothe-
lial function. Several reports have presented data on the
interaction between the sympathetic nervous system and
endothelial function. Thus, increased NO activity has been
observed during increased sympathetic tone. Sympathetic
activation elicited by mental stress results in a basal, NO-
mediated increase in both forearm (29) and coronary blood
flow (30). In agreement with this, cold pressor testing,
another frequently used sympathetic stress test, also results
in increased basal blood flow in the forearm (31) as well as
coronary arteries (32). The latter effects have been attributed
to NO synthase activation through beta2 (33,34) and/or
alpha2 receptor activation (35). Of note, these observations
describe sympathetic effects on basal NO availability in
microvascular resistance vessels. In contrast, in the present
study, we evaluated the effect of sympathetic activation
through baroreceptor unloading with LBNP on shear-
Figure 3. Effect of alpha-receptor blockade on the flow-mediated dilation
(FMD)/nitroglycerin (NTG) response with and without lower body
negative pressure (LBNP). (A) During phentolamine (PE) (solid squares),
the LBNP-induced impairment in FMD (solid circles) could no longer be
demonstrated (two-way repeated measures analysis of variance: *p  0.046
control vs. PE). (B) Phentolamine (solid squares) did not change the
NTG response compared with baseline (solid circles) (p  NS).
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stimulated NO release, assessed as FMD. We observed a
significant impairment in FMD during LBNP. These data
are in accordance with previous findings showing significant
FMD impairment during mental stress (29,36–38). The
discrepancy between shear-induced (macrovascular) and
agonist-induced (microvascular) NO synthase activation is
underscored by Engelke et al. (19), who demonstrated that
LBNP-induced sympathetic activation has no significant
effect on acetylcholine-induced microvascular vasodilation.
The impaired FMD response during LBNP can relate to
either increased vasoconstrictor tone, decreased shear stim-
ulus or decreased NO availability. The response to exoge-
nous NO remains intact, which argues against increased
nonspecific vasoconstrictor tone being responsible for the
impaired FMD response. Accordingly, it has been shown
that local noradrenalin infusion does not impair receptor-
mediated NO activity by metacholine infusion (39). The
second option—that is, decreased shear stimulus during
LBNP—is less likely, because the main determinants of
shear stress (i.e., basal brachial diameter, reactive hyperemic
blood flow and hematocrit) are comparable in the small time
frame before and after LBNP. Of note, one report (40) has
also suggested an association between basal shear stress
levels (in contrast to reactive hyperemia shear stress levels)
and FMD. However, it has recently been emphasized that
for assessment of NO-dependent endothelial function,
FMD responses to early flow, rather than sustained flow
changes, should be evaluated (41). Taken together, the
current data imply a specific inhibitory effect of sympathetic
activation on shear-mediated NO release. Few reports have
addressed this issue, although an inhibitory effect of
exercise-induced sympathetic stimulation on NO metabo-
lites has been reported in rat heart tissue (42). Further
research is needed to elucidate the exact interaction between
sympathetic activation and shear-stimulated NO produc-
tion by endothelial cells.
Study limitations. In this study, we assessed the heart rate
increase, rather than directly evaluating MSNA and/or
noradrenalin spillover as index of sympathetic activation.
However, we have previously demonstrated that MSNA at
a level of 20 mm Hg induces a mean increase in heart rate
of 15%, in addition to an increase in MSNA activity, within
a clinically relevant range, in healthy volunteers (14,22).
Hence, it is safe to assume that in the present study, the
LBNP of20 mm Hg, which resulted in a mean 15% heart
rate increase and a slight decrease in FBF, indeed produced
sympathetic stimulation in the volunteers.
Relevance for use of FMD in clinical trials. Flow-
mediated dilation has emerged as an attractive tool to
estimate endothelial function in patients. Over the last
decade, FMD as variable for endothelial dysfunction has
been successfully used to further characterize high-risk
groups, and the reversibility of impaired FMD responses
has been used to optimize pharmaceutical interventions in
patients at increased cardiovascular risk. The use of FMD
has increased because recent studies have shown the predic-
tive value of both coronary and brachial endothelial function
for future cardiovascular morbidity and mortality (3,4). In
the present report, we show that sympathetic activation has
a profound effect on the FMD response. This observation
may have direct consequences for the use of FMD for
patients with increased sympathetic outflow, such as in
those with heart failure, renal failure and hypertension. In
these patient groups, symptomatic treatment modalities,
which affect sympathetic outflow (e.g., diuretics, beta-
blockers), may result in improvement in FMD due to
changes in sympathetic activity. Hence, in studies evaluating
FMD as an indicator of endothelial dysfunction, the strong
effect of sympathetic activity on FMD should be taken into
account.
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